Daily Stock List
ROI Land Investments Ltd. (ROII)
Tiny Gems and Wallstreet Profiler reported previously on ROI Land Investments Ltd. (ROII), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
OTC Bulletin Board-listed ROI Land Investments Ltd. is a diversified real estate land development investment company. It participates in the early stages of real estate development. The Company acquires raw land free of zoning restrictions located in geographies positioned to benefit from unique economic catalysts. The Company formerly went by the name Conex MD Corp. It changed its corporate name to ROI Land Investments Ltd. in October 2013.
Furthermore, ROI Land Investments manages the permitting process, oversees the construction of infrastructure, and works closely with established developers to bring the projects to completion. ROI has projects underway across North America and the United Arab Emirates (UAE). Fundamentally, the Company concentrates on acquiring vacant land.
ROI looks for sites in leading growing regions where the price of land reflects the project’s potential profits. For the Company, the price of the land should be well within market norms. It should allow for maximum profitability. Land is purchased for immediate development with a projected profitable exit.
ROI’s business model comprises acquiring attractive land developments free of zoning restrictions, getting the required development permits, outsourcing the development of the infrastructure, and profiting from the sale of the subdivided land units to recognized large regional developers. It has a strategic network of construction companies, financial institutions, as well as owners of large land properties. ROI is working to further develop its existing projects in Colorado, U.S.A., and British Columbia, Canada.
ROI Land Investments has entered into a binding agreement to acquire 250 acres, or 10.9 million square feet, of land in Montgomery County, Texas for approximately $8.3 million. Its plan is to develop 900 residential housing units on the property. The property is 40 miles northwest of downtown Houston and next to the City of Conroe. The expectation is that this acquisition will close in Q1 2016.
In late December 2015, ROI Land Investments announced that it is expanding fund raising and capital markets activities in Germany to leverage the strong appetite for real estate investment opportunities among sophisticated investors. The Company has opened an office in Stuttgart that will serve as a focal point for its German operations.
ROI Land Investments Ltd. (ROII), closed Wednesday's trading session at $0.80, up 25.04%, on 25,475 volume with 20 trades. The average volume for the last 60 days is 22,795 and the stock's 52-week low/high is $0.413/$3.06.
Talon International, Inc. (TALN)
Greenbackers, Wallstreetlivechat, and OtcWizard reported earlier on Talon International, Inc. (TALN), and we choose to highlight the Company as well, here at the QualityStocks Daily Newsletter.
Talon International, Inc. is a leading international supplier of zippers, apparel fasteners, trim and stretch technology products. It supplies these to manufacturers of fashion apparel, specialty retailers, mass merchandisers, brand licensees, as well as major retailers around the world. Talon is the world’s original zipper brand founded in 1893.
Talon International has its corporate headquarters in Los Angeles, California. In addition, it has offices and facilities throughout the United States, the UK, Hong Kong, China, Taiwan, India, Indonesia and Bangladesh. The Company lists on the OTCQB.
Talon was the inventor of the zipper. It went on to pioneer a number of the innovations customary in zippers today. The Company’s TekFit® is its newest division. TekFit® has exclusive rights to advanced fabric technologies, which facilitate the addition of mechanical stretch into most standard fabrics.
The Company develops, manufactures and distributes custom zippers exclusively under its Talon® brand (The World's Original Zipper Since 1893). Furthermore, it designs, develops, manufactures, and distributes complete apparel trim solutions and products; and provides stretch technology for specialty waistbands, shirt collars, and other items all under its trademark and world renowned brands, Talon®, and TekFit®.
Top retailers globally recognize and use Talon products. These retailers include Abercrombie and Fitch, Polo Ralph Lauren, Kohl's, J.C. Penney, FatFace, Victoria's Secret, Wal-Mart, Tom Tailor, Levi Strauss & Co., Juicy Couture, and many others.
Talon International announced in September of 2015 that PVH Corp. (PVH) launched its Van Heusen Flex Collar men's dress shirts in retail stores. Flex Collar incorporates Talon's Tekfit® proprietary stretch technology. This permits expandable collar comfort with a half inch of stretch.
In November 2015, Talon International reported financial results for Q3 and nine months ended September 30, 2015. Selected highlights include Sales in Q3 2015 of $10.0 million. This represents a 15.0 percent decrease in comparison to Q3 2014. Moreover, Talon Tekfit stretch technology posted sales gains of $425,000 over Q3 2014. Additionally, new financing was obtained and a Credit Agreement amended with Talon International's bank, adding financial flexibility.
Talon International, Inc. (TALN), closed Wednesday's trading session at $0.15, even for the day. The average volume for the last 60 days is 8,691 and the stock's 52-week low/high is $0.0251/$0.251.
Cell MedX Corp. (CMXC)
The Observer, StockBlogs and SECFilings.com News reported earlier on Cell MedX Corp. (CMXC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Cell MedX Corp. is an early development stage company and it concentrates on the discovery, development, and commercialization of therapeutic products for patients with diseases, including diabetes. This is through developing technologies to help manage the illness and related complications. Cell MedX manufactures and distributes medical devices powered by its proprietary, patented technology of low level current chiefly for supporting chemical (pharmaceutical) treatments for diabetes. The Company is at the vanguard of creating devices, which treat chronic and acute conditions for clinical and self-management care. Cell MedX is based in Henderson, Nevada. The Company’s shares trade on the OTC Bulletin Board.
The Company is making safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, named cellular medicine. Moreover, via its wholly-owned subsidiary, Avyonce Cosmedics, Inc., the Company engages in the reselling and marketing of technology and equipment to the worldwide wellness industry and also providing continuing education to health care professionals.
Cell MedX’s goal is to release its initial lineup of commercial products early this year. The Company will begin with its flagship product named ‘e-Balance’, which works to improve the efficacy of the client’s existing medication regimes. The e-Balance brand includes consumer product development and professional versions for use within medical facilities. The design of them are to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance and blood pressure.
This past January, Cell MedX advised it now offers access to continuing observations of actual eBalance Professional (Pro) Series users. The observational reports can be found at www.cellmedx.com/observations. They will be updated often. The Company stated that new users are being actively solicited to participate in the ongoing research. Cell MedX expects the data will prove very useful to its development objectives.
Mr. Frank McEnulty, Cell MedX President and Chief Executive Officer, stated, "Our early results propelled us to commence the manufacture of additional units and to get them in use as quickly as possible. We are receiving excellent user responses to the device and its documented efficacy is on track and improvements will be duly noted as we increase our user base.”
Cell MedX Corp. (CMXC), closed Wednesday's trading session at $0.31, down 8.82%, on 40,600 volume with 8 trades. The average volume for the last 60 days is 7,332 and the stock's 52-week low/high is $0.0113/$0.39.
Propell Technologies Group, Inc. (PROP)
Greenbackers, Profitable Trading, and NBT Equities Research reported earlier on Propell Technologies Group, Inc. (PROP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Propell Technologies Group, Inc., via its wholly-owned subsidiary, Novas Energy USA, is the exclusive licensee of patented "Plasma Pulse" technology in the U.S. This technology has been shown to appreciably improve existing well recovery and production volumes. Propell Technologies Group is based in Houston, Texas. The Company is the U.S. and Mexico provider of the plasma pulse based well treatment.
The Company’s Novas Energy is an advanced technology and services enterprise whose aim is to substantially improve oil production by way of introducing modern and inventive technologies. Novas Energy USA’s Plasma-Pulse Treatment (PPT) is a new Enhanced Oil Recovery (EOR) technology and process. It has undergone development to be environmentally friendly, mobile, time efficient, and very cost effective. PPT is a technology that cleans a well’s perforation and bottom-hole zones. It also increases the permeability of the well while lessening the viscosity of the oil within the surrounding reservoir.
The Plasma Pulse enhanced oil recovery (EOR) well treatment improves well production cost effectively and without acidization, hydrofracking or other chemicals. It develops and commercializes treatment and stimulation of oil wells to greatly improve production and enhance the recovery of oil and gas in existing wells. Plasma Pulse is an easy-to-deploy technology. It utilizes vibrations, or electrically generated plasma impulses to reduce viscosity, increase permeability, and improve flow of oil and gas to the surface for extraction.
Propell Technologies earlier announced the operational launch of its previously announced joint venture between its wholly-owned subsidiary, Novas Energy USA and Technovita Technologies USA, Novas Energy North America (NENA). The creation of NENA is to sell and deliver oil well treatments using Plasma Pulse Technology, which had been licensed to Novas for the U.S. and Technovita for Canada. Technovita is a Calgary, Alberta based oil and gas technology service company.
This past January, Propell Technologies announced its objectives, including planning to enter the exploration and production (E&P) business, acquire producing assets and take advantage of its patented plasma pulse technology to improve production. The Company expects to acquire and grow distressed, producing assets through premier operational capabilities and efficiencies, and upon oil prices strengthening, concentrate on reserve value creation and asset divestiture to other entities who will pay premiums for reliable and optimized production, such as Master Limited Partnerships (MLPs).
The Company will transform itself into an E&P centered business through initiating a near term acquisition with production; employ plasma pulse technology as a major strategic edge over competitors to enhance production as applicable; and expand and redesign its plasma pulse technology licensing domestically and worldwide, among other objectives.
This month, Propell Technologies announced the appointment of Mr. David S. Ramsey as Chief Operating Officer (COO) effective March 1, 2016. Mr. Ramsey has wide-ranging experience in the oil and gas industry.
Propell Technologies Group, Inc. (PROP), closed Wednesday's trading session at $0.072, down 10.00%, on 12,115 volume with 6 trades. The average volume for the last 60 days is 112,257 and the stock's 52-week low/high is $0.05/$0.22.
RegeneRx Biopharmaceuticals, Inc. (RGRX)
Stock News Now, TopPennyStockMovers, and SmarTrend Newsletters reported previously on RegeneRx Biopharmaceuticals, Inc. (RGRX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company based in Rockville, Maryland. The Company concentrates on tissue protection, repair and regeneration with a complete portfolio of product candidates for first-in-class therapeutic peptides. Its corporate mission is to research and develop novel pharmaceuticals, which protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx Biopharmaceuticals’ shares trade on the OTC Markets’ OTCQB.
The Company holds multiple issued patents or filed patent applications around the world to enable and protect multiple indications and applications for its product candidates. It currently has three drug candidates in clinical development for ophthalmic, cardiac, and dermal indications. In addition, it has three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S. and has a broad international patent portfolio covering its products.
RegeneRx Biopharmaceuticals is focusing on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration. RGN-259, its TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary emphasis of the Company's clinical development efforts in the U.S.
RegeneRx was earlier allowed by the Food and Drug Administration (FDA) to move into Phase III clinical trials with RGN-259 for the treatment of patients with neurotrophic keratopathy (NK). RGN-259 is a Tβ4-based sterile eye drop. RegeneRx is developing this as a novel treatment for corneal healing. Moreover, the RGN-259 drug candidate is undergoing study in patients with dry eye syndrome in the U.S. and Asia. The Company, by way of its U.S. joint venture, ReGenTree LLC, is developing RGN-259 in the U.S.
RegeneRx Biopharmaceuticals’ management team is concentrating on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, the above-mentioned RGN-259 and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. RegeneRx is developing this as a novel treatment to hasten dermal healing. Additionally, RegeneRx is developing RGN-352. RGN-352 is its TB4-based injectable. This is a Phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events. This includes heart attacks, strokes, as well as other similar traumatic injuries.
This past January, RegeneRx Biopharmaceuticals announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC completed enrollment of its Phase 2b/3 dry eye trial in the U.S. The trial is testing RGN-259 (Thymosin beta 4), a sterile, preservative-free eye drop developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders.
RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Wednesday's trading session at $0.64, down 3.03%, on 117,078 volume with 80 trades. The average volume for the last 60 days is 42,008 and the stock's 52-week low/high is $0.211/$0.69.
Lingo Media Corp. (LMDCF)
The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.5859, even for the day. The stock’s average daily volume over the past 60 days is 4,431, and its 52-week low/high is $0.0862/$0.6745.
Lingo Media Corp. is pleased to announce that its subsidiary ELL Technologies Ltd. ("ELL Technologies") has completed development of its "ELL Studio," a speech recognition and practice pronunciation mobile app. With the development now complete, ELL Technologies plans to launch ELL Studio as a mobile app in the second quarter of 2016. "In line with the Company's commitment to Bring Your Own Device (BYOD) and to provide further accessibility to its customers around the world, we are pleased to release our first mobile app enabling our learners to practice their spoken English skills anywhere, anytime in the palm of their hand," said Gali Bar-Ziv, COO of Lingo Media. "With its personalized analysis of a learners' pronunciation, this innovative app takes speech recognition to the next level."
Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.
The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.
Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.
Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer
Lingo Media Corp. Company Blog
Lingo Media Corp. News:
Lingo Media's ELL Technologies to Launch "ELL Studio" App
Lingo Media Selected to the 2016 TSX Venture 50 & Ranked #1 In the Diversified Industries Sector
Lingo Media to Present at the World Outlook Financial Conference 2016 on January 29th & 30th
Halitron, Inc. (HAON)
The QualityStocks Daily Newsletter would like to spotlight Halitron, Inc. (HAON). Today, Halitron, Inc. closed trading at $0.005, on 1,422,883 volume with 55 trades. The stock’s average daily volume over the past 60 days is 233,135, and its 52-week low/high is $0.006/$0.05.
Halitron, Inc. today is excited to announce the acquisition of ArchivalMuseumSupplies, a leading direct marketing brand from Plastic Retail Displays, LLC. ArchivalMuseumSupplies is a brand that sells primarily archival-grade storage products like metal edge storage boxes, envelopes, sleeves, and bags unitizing archival-grade materials that help preserve valuable contents for an extended period of time. The brand's target customer base includes museums, libraries, archivists, and professional photographers. In an asset acquisition, Halitron, Inc. acquired a customer list totaling over 128,576 customers, the www.ArchivalMuseumSupplies.com website, and digital artwork files utilized for print and email blast campaigns.
Halitron, Inc. (HAON) is an equity holding company focused on the acquisition and efficient operation of sales, marketing and manufacturing businesses. The company primarily targets two types of acquisitions: bankrupt, distressed or insolvent businesses that can be inexpensively acquired and absorbed into Halitron's existing infrastructure; and profitable firms possessing a strategic operational fit that can benefit from Halitron's collective group of businesses. Following acquisition, businesses under Halitron's umbrella gain access to the company's established infrastructure, enabling the efficient and profitable manufacture and distribution of products.
Halitron's ongoing operations are structured into two strategic business units: a sales & marketing division and a manufacturing division. Through its sales & marketing division, the company owns operations in traditional marketing services and branded sales opportunities. Halitron's holdings through this division include NDG Holdings, Inc., a digital marketing services firm acquired in January 2015, and www.PiecesInPlaces.com, an online sales and marketing firm focused on office organization products acquired in February 2016. Through its manufacturing division, Halitron operates PRD Holdings, Inc., a Mexican manufacturing asset.
The company's management team is led by chief executive officer Bernard Findley. Over the past 20 years, Findley has amassed valuable experience promoting market growth in a variety of industries. During this time, he helped small- and mid-size businesses build up sales and seek out merger and acquisition opportunities. Over the past five years, Findley has rolled up and exited 16 bankrupt, insolvent or distressed brands, all of which continue to operate under new owners.
In February, Halitron set the stage for future growth when it entered into three separate letters of intent to make key profit generating acquisitions during the first quarter of 2016. When completed, these three acquisitions are expected to generate more than $1 million in annualized sales and establish the base of operations to lever future add-on acquisitions. "Over the past year we have positioned Halitron, Inc. to be a fast paced equity holding company, able to create significant shareholder wealth," Findley concluded in a news release. Disclaimer
Halitron, Inc. Company Blog
Halitron, Inc. News:
Halitron, Inc. Finalizes Third Acquisition in 2016
Halitron, Inc. Acquires www.PiecesInPlaces.com and PRD Holdings Inc. and Establishes the Fully Integrated Business Model
Halitron, Inc. (HAON) Lays Tracks for Success Built on Strong Acquisition, CEO Acumen
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $3.63, up 0.83%, on 7,369 volume with 25 trades. The stock’s average daily volume over the past 60 days is 8,995, and its 52-week low/high is $1.25/$11.625.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0184, up 2.79%, on 563,281 volume with 30 trades. The stock’s average daily volume over the past 60 days is 1,409,356 and its 52-week low/high is $0.0035/$0.339.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Agrees to Acquire Grupo Trebol in Guatemala City, Guatemala
Dominovas Energy Signs Financing Agreement With GHS Capital
Dr. Islam Lectures on the RUBICON Design -- The Industry's First Scalable Single Megawatt SOFC System
Star Mountain Resources, Inc. (SMRS)
The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $0.55, even for the day, on 16,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 7,901, and its 52-week low/high is $0.35/$1.40.
Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.
Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.
The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.
Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer
Star Mountain Resources, Inc. Company Blog
Star Mountain Resources, Inc. News:
Star Mountain Resources Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
Star Mountain Resources, Inc. Closes Acquisition of Balmat Zinc Mine in New York State
Star Mountain Resources, Inc. to Acquire Balmat Zinc Mine in New York State
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Agora Holdings, Inc. (AGHI) to Introduce Details of New Platform Next Week
- Alternet Systems (ALYI) Data Analytics Solution Gains Momentum with New Clients and Partners
- Cherubim Interests, Inc. (CHIT) Signs MOU to Acquire Revenue-Producing Company
- Dominovas Energy Corp. (DNRG) Agrees to Acquire Grupo Trebol in Guatemala City, Guatemala
- FlexWeek, Inc. (FXWK) Announces Engagement of QualityStocks Corporate Communications Suite
- Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
- GTX Corp. (GTXO) GPS SmartSole Showcased With Telefónica at CeBIT 2016
- Halitron, Inc. (HAON) Finalizes Third Acquisition in 2016
- Immune Therapeutics, Inc. (IMUN) Appoints Two New Board Members
- International Stem Cell Corp. (ISCO) to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
- Lingo Media Corp. (LMDCF) ELL Technologies to Launch "ELL Studio" App
- Moxian, Inc. (MOXC) Enters Into Exclusive Agreement and Development Partnership With Xinhua Media Affiliate
- Nutra Pharma Corp. (NPHC) to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
- Oakridge Global Energy Solutions, Inc. (OGES) Announces Strategic Business Alliance Agreement with Major Japanese Trading House
- OurPet's Company (OPCO) Unveils New Innovative Products at Global Pet Expo 2016
- Star Mountain Resources Inc. (SMRS) Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
- View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.